spacer
home > pmps > autumn 2003 > cryogenics leads the way in emissions control
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Cryogenics Leads the Way in Emissions Control

Emissions control has long been an important management issue for pharmaceutical manufacturers in Europe and beyond, but emerging legislation implemented throughout EU member states is forcing the industry to take a closer look at abatement technologies in search of solutions which will ensure compliance not just now, but in the future too.

Legislation puts Focus on Solvent Recovery

The manufacture of pharmaceutical products is reliant on a number of organic solvents, producing emissions in a number of process areas - from reactor vents to storage tanks and vacuum pumps. Dichloromethane, methanol, ethyl acetate, acetone, toluene, xylene, triethylamine, tetrahydrofurane, butyl acetate and isopropanol are among the VOCs regularly used by pharmaceutical manufacturers and legislation is limiting these emissions year on year. Industrial emissions to the atmosphere first became a focus of environmental regulation with the introduction of the Clean Air Act in 1993. Since then increasing concern about the effect of air pollutants on the environment has led to the development of the UK's National Air Quality Strategy, setting targets which are to be achieved by 2005.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Diana Raine, Business Manager for Cryogenics in Europe at Air Products

Diana Raine is Air Products' Business Manager for cryogenics in Europe and specialises in finding applications for cryogenic technology in modern industrial processes. She joined the company 12 years ago with a Masters in Chemical Engineering.

spacer
Diana Raine
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>

 
Industry Events

CPhI Worldwide

5-7 November 2019, Frankfurt, Germany

Join the World's Largest Pharma Event As it Celebrates its 30th Anniversary! Taking place from 5-7 November 2019 in Frankfurt, Germany, the event will bring together more than 45,000 visiting pharma professionals from around the globe and over 2,500 exhibiting pharma companies from every stage of the pharmaceutical supply chain - from ingredients and machinery to outsourcing services, packaging and more!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement